Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of ABI-007 Plus Sunitinib as First Line Treatment for Non-Small Cell Lung Cancer.

Next Previous
Search
Trial Profile

Phase II Study of ABI-007 Plus Sunitinib as First Line Treatment for Non-Small Cell Lung Cancer.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 29 Mar 2011 Planned End Date changed from 1 Dec 2008 to 1 Dec 2012 as reported by ClinicalTrials.gov.
  • 04 Jan 2011 Planned end date changed from 1 Sep 2015 to 1 Dec 2008 as reported by ClinicalTrials.gov.
  • 01 Mar 2009 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top